Ongoing clinical trials evaluating RET inhibitors and immunotherapy in MTC provide an opportunity to validate multi-marker panels that complement and extend beyond traditional biochemical biomarkers. This evidence concerns the gene RET and medullary thyroid gland carcinoma.